This two-day executive training which is organized for the 3^rd time in Athens by Boussias Events with the collaboration of Professor Panos Kanavos addresses the needs of employees in the pharmaceutical industry responsible for market access activities as well as stakeholders evolved in the Pricing & HTA decision making process to better understand the ‘Pricing & Value Assessment’ impact as well as insights and practice of a structured negotiation process based on real scenarios. Following previous years’ success, and according to the needs expressed by most participants, this year training will dive deeper into particulars of HTA processes in view of the new Joint HTA Regulation and also include practical examples of HTA to enable better understanding.

1. Expert Guidance: Professor Kanavos, an authority in HTA and negotiation, will share his wealth of knowledge, providing insights drawn from extensive research and real-world experiences.
2. Comprehensive Curriculum: Delve into the intricacies of HTA methodologies, economic evaluations, and negotiation techniques. The curriculum is designed to equip you with a holistic understanding of these critical areas.
3. Practical Application: Beyond theory, this training emphasizes hands-on applications. Through case studies and simulations, you will learn to apply HTA methodologies and negotiation strategies in diverse scenarios.
4. Networking Opportunities: Connect with fellow professionals, creating a valuable network of like-minded individuals. Exchange ideas, share experiences, and establish collaborations that extend beyond the training.
5. Customized Learning Paths: Tailor your learning experience. Whether you’re a healthcare professional, policymaker, or industry representative, the training is designed to accommodate diverse backgrounds and professional goals.

Prof. Panos Kanavos is ideally placed to deliver this training, not only due to his wide international experience in health economic evaluations, but also because he leads the activities of MTRG, which is a research group comprising of 13 researchers and concentrates on interdisciplinary and comparative policy research on medical technologies. The group conducts research on a number of research streams. As part of its activities, MTRG is currently co-ordinating the activities of the IMPACT HTA consortium, an EU H2020 grant, and has previously coordinated the activities of key research grants on Health Technology Assessment (Advance HTA project), on Chronic Disease and a component of Best Practices in Rare Diseases. It has conducted research under the auspices of and participated in the European Medicines Information Network (EMI-net) and the network for the study of rare diseases. It also coordinates the activities of The Patient Academy, an initiative between academia, health care regulatory agencies and patient groups. in the preparation, conduct and/or supervision of over 400 HTAs in recent years.

Mackenzie Mills, Assistant Director, Medical Technology Research Group, LSE Health has worked in the field of health policy for several years, with a focus on market access, health technology assessment, sustainable financing, and drug pricing. Mackenzie’s previous work involves global consulting and research activities, speaking engagements at several conferences across Europe, and a number of publications. He has facilitated a range of executive training courses including the LSE Market Access Academy and the WHO workshop on strategic procurement with a focus on negotiations. Mackenzie holds a BSc in Biochemistry (University of British Columbia, Canada) and an MSc in International Health Policy (LSE, UK).

One of the most valuable aspects of attending this executive training e is not only being able to have your specific questions answered by leading experts, but also having the opportunity to share experiences and have in-depth discussions with your peers as well as test your strengths and weaknesses during a price negotiation’s process.

The typical audience size of the courses ranges from 50 to 60 (max) participants.

This course will be of great benefit to those who prepare for the HTA and Price Negotiation Process- i.e. executives in pharma, diagnostics and medical device companies involved in the provision of clinical, economic and other required data (e.g. ethical) and participate in the negotiation process with the Price Negotiation Committee of the Ministry of Health.

In addition, this course will be valuable to everyone for whom understanding the principles behind HTA, its usage and value is critical in their function, such as:

• Market Access
• Pricing & Reimbursement
• Medical

• Health Economics
• Regulatory Affairs
• Marketing
• Healthcare Professionals
• Government Officials
• Researchers in Health Economics and HTA

Finally, the HTA & Price Negotiation bodies themselves and all those who have to deal with the implications of HTA in practice (physicians, health insurance companies, hospitals and other decision makers) would benefit from attending.